Aerosol Chamber for in Vivo Pre-Clinical Testing of Inhaled Dry Powders

Artist rendering of lungs
Opportunity

Available for Licensing
TRL: 7

IP Status

US Utility Patent Pending (Not Yet Published)

Inventors

Mercedes Gonzalez-Juarrero
Jeffrey Mariner Gonzalez

At A Glance

Researchers at Colorado State University have developed an aerosol chamber for low dose administration of dry powder medications to animals. This new chamber allows for administration of long term therapies in preclinical in vivo studies at biologically significant levels, while keeping the animals calm and relaxed. This allows for more clinically relevant studies, and the removal of some confounding variables in preclinical dry powder medication studies.

For more details, please contact our office!

Licensing Director

Jessy McGowan
Jessy.McGowan@colostate.edu
970-491-7100

Reference No.:  2022-051

Background

There is an unmet need for testing the efficacy of dry powders in preclinical studies. Studies requiring daily and long-term (months) administration of drugs via inhalation are limited by lack of appropriate inhalational devices. Current inhalation devices are not suitable for this purpose because they require the use of very large quantities of dry powders and because conscious animals must be restrained into chambers. These restraining techniques place the animal under enough stress to make long term exposure both ineffective and untenable.

Technology Overview

The passive inhalation chamber presented here allows for creation of aerosol of dry powder within an anesthetizing environment. Since the aerosol is in a standing cloud the dry powder drug is recycled within the chamber, meaning far less loading of the drug is needed to achieve inhalation at biologically active levels. This improves efficiency of the drug used and allows for research to be conducted on compounds and drugs that are not in mass production or are otherwise highly cost or supply constrained.

The chamber allows for multiple doses and allows the subjects to relax far more than the current methods of preclinical testing.

Benefits
  • Reduced amount of dry powder needed for preclinical study
  • Ability to study long term dosages and effects of multiple doses
  • More accurate and biologically relevant research due to
    • More accurate dosing
    • Subject relaxation
    • Administration of powder is more biomimetic
Applications
  • Drug development of dry powders
  • Long term exposure studies
  • Multiple dose studies
  • Antibiotic delivery
  • Aerosolized drug delivery and study (i.e. steroids, bronchodialators, etc)
Pre-Clinical Data
  • Initial results available upon request

Last updated: May 2022

Add keywords or various names of inventors here (text is hidden)

Aerosol chamber, preclinical studies, micronized powders, dry powders

DSI, Kent animals laboratories, EMMS, Anschutz, Palas, Lovelace Respiratory Research Institute etc